标题
BRAF inhibition improves tumor recognition by the immune system
作者
关键词
-
出版物
OncoImmunology
Volume 1, Issue 9, Pages 1476-1483
出版商
Informa UK Limited
发表日期
2012-10-01
DOI
10.4161/onci.21940
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Dissection of T-cell Antigen Specificity in Human Melanoma
- (2012) R. S. Andersen et al. CANCER RESEARCH
- BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy
- (2012) Richard C. Koya et al. CANCER RESEARCH
- BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency
- (2012) D. S. Hong et al. CLINICAL CANCER RESEARCH
- Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers
- (2012) Rikke Sick Andersen et al. Nature Protocols
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- TIL therapy broadens the tumor-reactive CD8+T cell compartment in melanoma patients
- (2012) Pia Kvistborg et al. OncoImmunology
- Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures
- (2011) Niels Junker et al. CELLULAR IMMUNOLOGY
- White Paper on Adoptive Cell Therapy for Cancer with Tumor-Infiltrating Lymphocytes: A Report of the CTEP Subcommittee on Adoptive Cell Therapy
- (2011) J. Weber et al. CLINICAL CANCER RESEARCH
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- (2011) James S. Wilmott et al. CLINICAL CANCER RESEARCH
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- A Phase 1 Study of a Vaccine Targeting Preferentially Expressed Antigen in Melanoma and Prostate-specific Membrane Antigen in Patients With Advanced Solid Tumors
- (2011) Jeffrey S. Weber et al. JOURNAL OF IMMUNOTHERAPY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Characterization and Comparison of ‘Standard’ and ‘Young’ Tumour-Infiltrating Lymphocytes for Adoptive Cell Therapy at a Danish Translational Research Institution
- (2011) M. Donia et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
- (2010) A. Boni et al. CANCER RESEARCH
- The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations
- (2010) B. Comin-Anduix et al. CLINICAL CANCER RESEARCH
- Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
- (2010) Jill C Rubinstein et al. Journal of Translational Medicine
- Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032
- (2010) Jonas N Søndergaard et al. Journal of Translational Medicine
- KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
- (2009) Susan D. Richman et al. JOURNAL OF CLINICAL ONCOLOGY
- The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines
- (2008) Rikke Bæk Sørensen et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Combining MHC tetramer and intracellular cytokine staining for CD8+ T cells to reveal antigenic epitopes naturally presented on tumor cells
- (2008) Nektaria Dimopoulos et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Heat-shock protein 90 associates with N-terminal extended peptides and is required for direct and indirect antigen presentation
- (2008) M. K. Callahan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started